Filed under: adrenal | Tagged: abdominal pain, abstract, adrenal insufficiency, anorexia, CAH, children, Congenital adrenal hyperplasia, congenital adrenal hypoplasia, fatal, fatigue, hyperpigmentation, hypotension, salt craving, weakness, weight loss | Leave a comment »
Primary Adrenal Insufficiency (PAI)
Cushing’s appears to begin its cardiovascular effects during childhood
ORLANDO – Cushing’s disease may begin to exert its harmful cardiovascular effects quite early, a small pediatric study has found.
Children as young as 6 years old with the disorder already may show signs of cardiovascular remodeling, with stiffer aortas and higher aortic pulse-wave velocity than do age-matched controls, Hailey Blain and Maya Lodish, MD, said at the annual meeting of the Endocrine Society.
“The study, which included 10 patients, is small, but we continue to add new patients,” said Dr. Lodish, director of the pediatric endocrinology fellowship program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Ten more children are being added to the cohort now, and she and Ms. Blain, a former research fellow at NIH, intend to grow the group and follow patients longitudinally.
Cushing’s disease has long been linked with increased cardiovascular risk in adults, but the study by Dr. Lodish and Ms. Blain is one of the first to examine the link in children. Their findings suggest that early cardiovascular risk factor management should be a routine part of these patients’ care, Dr. Lodish said in an interview.
“It’s very important to make sure that there is recognition of the cardiovascular risk factors that go along with this disease. Elevated levels of cholesterol, hypertension, and other risk factors that are in these individuals should be ameliorated as soon as possible from an early age and, most importantly, physicians should be diagnosing and treating children early, once they are identified as having Cushing’s disease. And, given that we are not sure whether these changes are reversible, we need to make sure these children are followed very closely.”
Indeed, Dr. Lodish has reason to believe that the changes may be long lasting or even permanent.
“We are looking at these children longitudinally and have 3-year data on some patients already. We want to see if they return to normal pulse wave velocity after surgical cure, or whether this is permanent remodeling. There is an implication already that it may be in a subset of individuals,” she said, citing her own 2009 study on hypertension in pediatric Cushing’s patients. “We looked at blood pressure at presentation, after surgical cure, and 1 year later. A significant portion of the kids still had hypertension at 1 year. This leads us to wonder if they will continue to be at risk for cardiovascular morbidity as adults.”
Ms. Blaine, an undergraduate at Bowdoin College, Brunswick, Maine, worked on the study during a summer internship with Dr. Lodish and presented its results in a poster forum during meeting. She examined two indicators of cardiovascular remodeling – aortic pulse wave velocity and aortic distensibility – in 10 patients who were a mean of 13 years old. All of the children came to NIH for diagnosis and treatment of Cushing’s; as part of that, all underwent a cardiac MRI.
The patients had a mean 2.5-year history of Cushing’s disease Their mean midnight cortisol level was 18.8 mcg/dL and mean plasma adrenocorticotropic hormone level, 77.3 pg/mL. Five patients were taking antihypertensive medications. Low- and high-density lipoprotein levels were acceptable in all patients.
The cardiovascular measures were compared to an age-matched historical control group. In this comparison, patients had significantly higher pulse wave velocity compared with controls (mean 4 vs. 3.4 m/s). Pulse wave velocity positively correlated with both midnight plasma cortisol and 24-hour urinary free cortisol collections. In the three patients with long-term follow-up after surgical cure of Cushing’s, the pulse wave velocity did not improve, either at 6 months or 1 year after surgery. This finding echoes those of Dr. Lodish’s 2009 paper, suggesting that once cardiovascular remodeling sets in, the changes may be long lasting.
“The link between Cushing’s and cardiovascular remodeling is related to the other things that go along with the disease,” Dr. Lodish said. “The hypertension, the adiposity, and the high cholesterol all may contribute to arterial rigidity. It’s also thought to be due to an increase in connective tissue. The bioelastic function of the aorta may be affected by having Cushing’s.”
That connection also suggests that certain antihypertensives may be more beneficial to patients with Cushing’s disease, she added. “It might have an implication in what blood pressure drug you use. Angiotensin-converting enzyme inhibitors increase vascular distensibility and inhibit collagen formation and fibrosis. It is a pilot study and needs longitudinal follow up and additional patient accrual, however, finding signs of cardiovascular remodeling in young children with Cushing’s is intriguing and deserves further study.”
Neither Ms. Blain nor Dr. Lodish had any financial disclosures.
Filed under: Cushing's, Meetings and Conferences, symptoms | Tagged: AACE 2017 Annual Meeting, American Association of Clinical Endocrinologists, aorta, cardiovascular, children, cholesterol, Cushing's Disease, hypertension, National Institutes of Health, NIH, pediatric | Leave a comment »
Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism
MENLO PARK, CA — (Marketwired) — 05/04/17 — Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that presentations about hypercortisolism and mifepristone’s role in treating that disorder will be presented at the 26th Annual Congress of the American Association of Clinical Endocrinologists (AACE) being held at the Austin Convention Center in Austin, Texas.
“There is growing awareness that even less severe degrees of hypercortisolism are harmful,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “As a result, physicians are increasingly screening patients whose metabolic and cardiovascular symptoms have not responded to conventional therapy and finding cases of previously undetected Cushing’s syndrome.”
In addition to viewing the posters described below, AACE attendees may attend “Evolving Paradigms of Hypercortisolism,” a product theater talk by Ty Carroll, M.D. Corcept is a sponsor of the talk.
----------------------------------------------------------------------------
Thursday, May 4, 2017
----------------------------------------------------------------------------
Poster #124
Screening of Diabetic Patients Using
U500
Insulin Uncovers a High Percentage of Joseph W. Mathews, M.D., FACE
Undiagnosed Hypercortisolism James J. Smith, PhD
Consistent
with Cushing Syndrome
----------------------------------------------------------------------------
Friday, May 5, 2017, 12:45 - 1:30pm
Product Theater B
----------------------------------------------------------------------------
Evolving Paradigms of
Hypercortisolism Ty Carroll, M.D.
----------------------------------------------------------------------------
Friday, May 5, 2017
----------------------------------------------------------------------------
Poster #131
Medical Management of Mild
Hypercortisolism and Primary
Aldosteronism in a Patient with Sandi-Jo Galati, M.D.
ACTH-Independent Macronodular Michele Lamerson, RN, MS, CPNP
Hyperplasia
Presenting with Resistant
Hypertension
----------------------------------------------------------------------------
Adriana G. Ioachimescu, M.D., PhD, FACE
Poster #608 Jonathan G. Ownby, M.D., FACE
Improving Glycemic Control with Nicole G. Greyshock, M.D., FACE
Mifepristone Thomas C. Jones, M.D., FACE
in Cushing Syndrome Patients May Lead Gary S. Wand, M.D., PhD, FACE
to Significant Weight-loss James J. Smith, PhD
----------------------------------------------------------------------------
Poster #725
Successful Medical Management with Saima Farghani, M.D.
Mifepristone in a Patient with Occult Michele Lamerson, RN, MS, CPNP
Ectopic Cushing Syndrome
----------------------------------------------------------------------------
Poster #836
Mifepristone Therapy Significantly
Improved
Insulin Resistance, Glycemic Control, Jonathan G. Ownby, M.D., FACE
and Weight Loss in a Patient with James J. Smith, PhD
Cushing Disease
Previously Treated with Pasireotide
----------------------------------------------------------------------------
Poster #839
Mifepristone Reduced U500 Insulin
Usage in a Patient with Cushing Kimberley A. Bourne, M.D., FACE
Disease and Normalized Concomitant James J. Smith, PhD
Fatty Liver Disease and Retinopathy
----------------------------------------------------------------------------
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company’s first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
From http://news.sys-con.com/node/4073068
Filed under: Cushing's, Meetings and Conferences, Treatments | Tagged: AACE 2017 Annual Meeting, American Association of Clinical Endocrinologists, Corcept, cortisol, Cushing's Syndrome, Dr. Ty Carroll, hypercortisolism, Korlym, mifepristone, pasireotide | Leave a comment »
